Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

Therapeutic Advances in Medical Oncology
Fan ZhangYi Hu

Abstract

Immunotherapy combined with platinum-based chemotherapy is now the standard first-line treatment for non-small cell lung cancer (NSCLC) patients. However, limited evidence exists to show the efficacy of immunotherapy plus taxanes for patients who have progressed after platinum-based chemotherapy. The immunotherapy naïve patients with metastatic NSCLC who received anti-PD-1/PD-L1 monotherapy or combined with nab-paclitaxel after prior platinum-based chemotherapy from 2015 to 2018 in PLA General Hospital were identified. The progression-free survival, overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety were assessed. Of 57 patients, 40 were treated with anti-PD-1/PD-L1 monotherapy and 17 were treated with anti-PD-1/PD-L1 plus nab-paclitaxel. With a median OS follow-up of 16.3 months, the nab-paclitaxel group showed significantly longer OS compared with the immune monotherapy group (median, 28.6 months versus 15.9 months, log-rank p = 0.020). When adjusted by covariates in COX proportional regression model, both the treatment group [p = 0.009, hazard ratio (HR) 0.361; 95% confidence interval (CI) 0.168-0.773] and performance status (p = 0.003, HR 0.372; 95% CI 0.192-0.721) demonstrated indep...Continue Reading

References

Jun 3, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R GreenM J Hawkins
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naiyer A RizviMark G Kris
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Panos M FidiasJoan H Schiller
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio ScagliottiNasser Hanna
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stanleyson V HatoW Joost Lesterhuis
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 6, 2015·Cancer Immunology Research·Leisha A Emens, Gary Middleton
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Aug 28, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Shinya SakataHirotsugu Kohrogi
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Mar 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerJulie Brahmer
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Sep 1, 2018·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Pedro Miguel Lacal, Grazia Graziani
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Jan 12, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Julia Jiménez-LópezConsolación Melguizo
Mar 17, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
May 8, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Amy L ShergoldRobert J B Nibbs
Aug 8, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Li WangXiaochun Zhang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
SPSS
GraphPad

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.